1Stubbings W, Leow P,Yong GC ,et,al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions [ J ]. Antimicrob Agents Chemother, 2011,55 ( 9 ) : 4394-4397.
4Van Bambeke F. Renaissance of antibiotics against difficult infec- tions:Focus on oritavancin and new ketolides and quinolones [ J ]. Ann Meal,2014,46(7 ) :512-529.
5Higgins PG, Stubbings W, Wisplinghoff H,et, al. Activity of the inves- tigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates[ J]. Antimicrob Agents Chemother,2010,54(4 ) : 1613-1615.
6Karpiuk I ,Tyski S. Looking for the new preparations for antibacterial therapy. II Clinical trials ; new beta-lactam antibiotics and beta-lacta- mase inhibitors [ J]. Przegl Epidemiol,2013,67 ( 1 ) :51-56,135-140.
7Idelevich EA, Kriegeskorte A, Stubbings W, et, al. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes [ J ]. J Antimicrob Chemother, 2011,66(12) :2809-2813.
8Lemaire S, Van Bambeke F, Tulkens PM. Activity of finafloxaein, a novel fluorequinolone with increased activity at acid pH, towards ex- tracellular and intracelluiar Staphylococcus aureus, Listeria monocyto- genes and Legionella pneumophila[ J]. Int J Antimicrob Agents,2011, 38(1) :52-59.
9Emrich NC, Heisig A,Stubbings W, et, al. Antibacterial activity of fin- afloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fiuoroquinolone resistance [ J ]. J Antimicrab Chemother, 2010, 65 (12) :2530-2533.
10Pate] H, Andresen A, Vente A, et, al. Human pharmacokinetics and safety profile of finafloxacin, a new fiuorequinolone antibiotic, in healthy volunteers [ J ]. Antimicrob Agents Chemother, 2011,55 ( 9 ) : 4386-4393.
